Business Daily Media

Men's Weekly

.

Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia

  • Written by ACN Newswire - Press Releases

Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia

ADELAIDE, AUS, Jul 9, 2021 - (ACN Newswire) - The largest Australian full-service CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client Tetherex Pharmaceuticals on first patient dosing for its Phase 1 vaccine clinical trial.
Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia
Tetherex Pharmaceuticals, Inc.

Read more //?#

Refunds to Revenue: AI and loyalty perks help retailers in post-holiday hangover

Australian retailers are turning to artificial intelligence to simplify and automate returns and exchanges, while strengthening loyalty programs a...

Stop reading from the script: Why authenticity is the customer success secret weapon

I’ve been in customer service for years now. As my team has grown, the number one piece of advice I give is to be your...

From Check-in to Touchdown: How AI and smarter systems are transforming the travel industry

Richard Valente, VP of Customer Experience Strategy at TP in Australia, explores how IT-BPM outsourcing is revolutionising the travel sector throu...

Online Christmas shoppers fund climate and biodiversity projects via HealthPost's Click Sphere for Good initiative

Online shoppers with HealthPost’s Flora & Fauna have made 11,000 contributions towards climate and biodiversity projects when ordering parcel ...

US landmark settlement protects SMEs, highlighting flaws in the RBA's proposed blanket card surcharging ban for Australia

Aussie SMEs warn RBA not to ignore global trends, with the current sledgehammer approach threatening business viability and increasing inflation ...

Thryv Australia named Employer of Choice for third consecutive year at Australian Business Awards

Thryv® (NASDAQ: THRY), Australia’s provider of the leading small business marketing and sales software platform, has been awarded the Employer of ...